CRISPR Therapeutics CRSP Return on invested capital

Return on invested capital at other companies

Ultragenyx PharmaceuticalRARE

-475.4%+443pp

Intellia TherapeuticsNTLA

-62.8%+0.9pp

Allogene TherapeuticsALLO

-51.3%-5.7pp

Beam TherapeuticsBEAM

-39.4%-8.8pp

Sana BiotechnologySANA

-157.6%+1,210pp

Design Therapeutics, Inc.DSGN

-37.1%+12.1pp

FAQ

What is CRISPR Therapeutics's return on invested capital?

CRISPR Therapeutics (CRSP) reported return on invested capital of -32.4% in Q1 2026.

How has CRISPR Therapeutics's return on invested capital changed year-over-year?

CRISPR Therapeutics's return on invested capital decreased by 16.9% year-over-year, from -27.7% to -32.4%.

What is the long-term trend for CRISPR Therapeutics's return on invested capital?

Over 3 years (2020 to 2025), CRISPR Therapeutics's return on invested capital has grown at a -32.2% compound annual growth rate (CAGR), from -117.1% to -36.5%.

What does return on invested capital mean?

Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.